Journal article
MLX plays a key role in lipid and glucose metabolism in humans: evidence from in vitro and in vivo studies
- Abstract:
-
Background and aim
Enhanced hepatic de novo lipogenesis (DNL) has been proposed as an underlying mechanism for the development of NAFLD and insulin resistance. Max-like protein factor X (MLX) acts as a heterodimer binding partner for glucose sensing transcription factors and inhibition of MLX or downstream targets has been shown to alleviate intrahepatic triglyceride (IHTG) accumulation in mice. However, its effect on insulin sensitivity remains unclear. As human data is lacking, the aim of the present work was to investigate the role of MLX in regulating lipid and glucose metabolism in primary human hepatocytes (PHH) and in healthy participants with and without MLX polymorphisms.Methods
PHH were transfected with non-targeting or MLX siRNA to assess the effect of MLX knockdown on lipid and glucose metabolism, insulin signalling and the hepatocellular transcriptome. A targeted association analysis on imputed genotype data for MLX on healthy individuals was undertaken to assess associations between specific MLX SNPs (rs665268, rs632758 and rs1474040), plasma biochemistry, IHTG content, DNL and gluconeogenesis.Results
MLX knockdown in PHH altered lipid metabolism (decreased DNL (p < 0.05), increased fatty acid oxidation and ketogenesis (p < 0.05), and reduced lipid accumulation (p < 0.001)). Additionally, MLX knockdown increased glycolysis, lactate secretion and glucose production (p < 0.001) and insulin-stimulated pAKT levels (p < 0.01) as assessed by transcriptomic, steady-state and dynamic measurements. Consistent with the in vitro data, individuals with the rs1474040-A and rs632758-C variants had lower fasting plasma insulin (p < 0.05 and p < 0.01, respectively) and TG (p < 0.05 and p < 0.01, respectively). Although there was no difference in IHTG or gluconeogenesis, individuals with rs632758 SNP had notably lower hepatic DNL (p < 0.01).Conclusion
We have demonstrated using human in vitro and in vivo models that MLX inhibition favored lipid catabolism over anabolism and increased glucose production, despite increased glycolysis and phosphorylation of Akt, suggesting a metabolic mechanism that involves futile cycling.
- Publication status:
- Published
- Peer review status:
- Peer reviewed
Actions
Access Document
- Files:
-
-
(Preview, Version of record, pdf, 6.2MB, Terms of use)
-
- Publisher copy:
- 10.1016/j.metabol.2023.155563
Authors
+ Biotechnology and Biological Sciences Research Council
More from this funder
- Funding agency for:
- Hodson, L
- Grant:
- BB/N005600/1
- BB/N015665/1
+ British Heart Foundation
More from this funder
- Funding agency for:
- Hodson, L
- Grant:
- FS/15/56/31645
- FS/SBSRF/21/31013
+ Biotechnology and Biological Sciences Research Council Institute Strategic Programme Food Innovation and Health
More from this funder
- Funding agency for:
- Hodson, L
- Grant:
- BBS/E/F/000PR10347
- BB/R012512/1
+ Oxford British Heart Foundation Centre of Research Excellence
More from this funder
- Grant:
- RE/18/3/34214
- Publisher:
- Elsevier
- Journal:
- Metabolism More from this journal
- Volume:
- 144
- Article number:
- 155563
- Publication date:
- 2023-04-21
- Acceptance date:
- 2023-04-17
- DOI:
- ISSN:
-
0026-0495
- Language:
-
English
- Keywords:
- Pubs id:
-
1337617
- Local pid:
-
pubs:1337617
- Deposit date:
-
2023-04-19
- ARK identifier:
Terms of use
- Copyright holder:
- Nagarajan et al.
- Copyright date:
- 2023
- Rights statement:
- © 2023 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
- Licence:
- CC Attribution (CC BY)
If you are the owner of this record, you can report an update to it here: Report update to this record